#RAforum

Bart Peterson, JD, Senior Vice President for Corporate Affairs and Communications at Eli Lilly , and the keynote speaker of the Research!America’s National Research Health Forum talked with Medscape about the future of research and drug development, and whether cooperation between industry and the US Food and Drug Administration (FDA) can ever truly exist. To see the interview, click here .
Research!America’€™s National Health Research Forum ’€” held September 12 at the Newseum’€™s Knight Conference Center in Washington, DC ’€” examined the current and future state of research to improve health. This year’€™s theme was ’€œStraight Talk about the Future of Medical and Health Research.’€ Three expert panels delved into different aspects of the research ecosystem. Research!America’€™s president and CEO, Mary Woolley, and chair, The Honorable John Edward Porter, opened the program. Porter introduced Bart Peterson, JD, senior vice president of corporate affairs and communications at Lilly who delivered a brief keynote speech. ’€œWe developed an innovation ecosystem, and that...
Research!America’€™s National Health Research Forum ’€” held September 12 at the Newseum’€™s Knight Conference Center in Washington, DC ’€” examined the current and future state of research to improve health. This year’€™s theme was ’€œStraight Talk about the Future of Medical and Health Research.’€ Three expert panels delved into different aspects of the research ecosystem. Research!America’€™s president and CEO, Mary Woolley, and chair, The Honorable John Edward Porter, opened the program. Porter introduced Bart Peterson, JD, senior vice president of corporate affairs and communications at Lilly who delivered a brief keynote speech. ’€œWe developed an innovation ecosystem, and that...
Dear Research Advocate: The Bureau of Economic Analysis has reclassified research and development costs from an “expense” to an “investment” when calculating GDP. We think Members of Congress should do the same. Common sense tells us R&D is an investment, not an expense; in general conversation we all talk about R&D as an investment, but it isn’€™t accounted for that way on the federal books. The arguments we’€™ve been making are now further bolstered by the BEA’€™s decision. Spread the word! One hundred and sixty five university presidents and chancellors, representing all 50 states, have called on the president and Congress to reverse the pending “innovation deficit” in an open...
Dear Research Advocate: The Bureau of Economic Analysis has reclassified research and development costs from an “expense” to an “investment” when calculating GDP. We think Members of Congress should do the same. Common sense tells us R&D is an investment, not an expense; in general conversation we all talk about R&D as an investment, but it isn’€™t accounted for that way on the federal books. The arguments we’€™ve been making are now further bolstered by the BEA’€™s decision. Spread the word! One hundred and sixty five university presidents and chancellors, representing all 50 states, have called on the president and Congress to reverse the pending “innovation deficit” in an open...

Sidebar Quote

We have health challenges in this country that science will provide answers for if given the chance and we haven't given science that opportunity
Mary Woolley, President and CEO, Research!America